Department of Pharmacy, The Second Affiliated Hospital, Shantou University Medical College, Shantou, China.
Department of Pharmacy, Cancer Hospital of Shantou University Medical College, Shantou, China.
BMC Cardiovasc Disord. 2024 Feb 15;24(1):109. doi: 10.1186/s12872-024-03768-4.
Early diagnosis of atrial fibrillation is important as it is crucial for improving patient outcomes. Fibroblast growth factor-2 (FGF2) may serve as a diagnostic biomarker for heart failure due to its ability to promote cardiac fibrosis and hypertrophy; however, the relationship between FGF2 concentration and heart failure is unclear. Therefore, this study aimed to explore whether FGF2 could aid in distinguishing patients with heart failure from healthy controls and those with dyspnea without heart failure. Additionally, to evaluate the possible correlation between serum FGF2 levels and its diagnostic parameters in patients with heart failure.
Plasma FGF2 concentration was measured in 114 patients with a complaint of dyspnea (enrolled in the study between January 2022 and August 2022). Based on heart failure diagnosis, the patients were assigned to three groups, as follows: heart failure (n = 80), non-heart-failure dyspnea (n = 34), and healthy controls (n = 36), following physical examination. Possible correlations between serum FGF2 levels and other prognostic parameters in patients with heart failure were analyzed.
Serum FGF2 levels were higher in patients with heart failure (125.60 [88.95, 183.40] pg/mL) than in those with non-heart-failure dyspnea (65.30 [28.85, 78.95] pg/mL) and healthy controls (78.90 [60.80, 87.20] pg/mL) (p < 0.001). Receiver operating characteristic curve analysis identified FGF2 concentration as a significant predictor in heart failure diagnosis, with an area under the curve of 0.8693 (p < 0.0001). Importantly, in the heart failure group, serum FGF2 concentrations correlated with key prognostic parameters for heart failure, such as reduced left ventricular ejection fraction and elevated serum levels of N-terminal pro-B-type natriuretic peptide.
Elevated serum FGF2 level is strongly associated with an increased risk of heart failure and could serve as a useful biomarker to complement vital diagnostic parameters for heart failure.
早期诊断心房颤动很重要，因为这对于改善患者预后至关重要。成纤维细胞生长因子 2（FGF2）可促进心肌纤维化和肥大，因此可能成为心力衰竭的诊断生物标志物；然而，FGF2 浓度与心力衰竭之间的关系尚不清楚。因此，本研究旨在探讨 FGF2 是否有助于区分心力衰竭患者与健康对照者和呼吸困难但无心力衰竭患者。此外，评估心力衰竭患者血清 FGF2 水平与其诊断参数之间的可能相关性。
测量 114 例呼吸困难患者（于 2022 年 1 月至 2022 年 8 月期间入组研究）的血浆 FGF2 浓度。根据心力衰竭诊断，将患者分为三组：心力衰竭组（n=80）、非心力衰竭性呼吸困难组（n=34）和健康对照组（n=36），通过体格检查进行分组。分析心力衰竭患者血清 FGF2 水平与其他预后参数之间的可能相关性。
心力衰竭患者的血清 FGF2 水平（125.60[88.95，183.40]pg/mL）高于非心力衰竭性呼吸困难患者（65.30[28.85，78.95]pg/mL）和健康对照组（78.90[60.80，87.20]pg/mL）（p<0.001）。受试者工作特征曲线分析表明，FGF2 浓度是心力衰竭诊断的一个显著预测因子，曲线下面积为 0.8693（p<0.0001）。重要的是，在心力衰竭组中，血清 FGF2 浓度与心力衰竭的关键预后参数相关，如左心室射血分数降低和血清 N 末端 pro-B 型利钠肽水平升高。
血清 FGF2 水平升高与心力衰竭风险增加密切相关，可作为心力衰竭补充重要诊断参数的有用生物标志物。
